Skip to content

    Piramal Pharma

    PPLPHARMAGood
    Healthcare·15 May 2025
    Management Summary

    Piramal Pharma delivered a strong finish to FY25, hitting the $1 billion revenue milestone and significantly improving profitability. However, management proactively flagged a transition year in FY26, where revenue growth will slow to mid-single digits as a major CDMO customer normalizes inventory following a blockbuster launch. The company remains bullish on its long-term FY30 targets, supported by capacity expansions in the US and a shift toward high-margin innovation-led CDMO work.

    Highlights

    8

    • Surpassed USD 1 billion annual revenue milestone in FY25 with 12% YoY growth.

    • FY25 EBITDA margin reported at 17%, representing 15% YoY EBITDA growth.

    • Net Profit After Tax (PAT) for FY25 increased 5x to ₹91 crores from ₹18 crores in the previous year.

    • CDMO business delivered 15% revenue growth in FY25, with innovation-related work contributing 54% of segment revenue.

    • Complex Hospital Generics (CHG) crossed $300 million in revenue, maintaining 44% US market share in Sevoflurane.

    • India Consumer Healthcare (ICH) exceeded ₹1,000 crores in annual revenue with 20%+ growth in Power Brands.

    • Management guided for a 'muted' FY26 (mid-single-digit growth) due to inventory normalization by a major CDMO customer.

    • Reiterated FY30 aspiration to become a $2 billion company with 25% EBITDA margins.

    Concerns

    1

    • Customer Concentration & Inventory Normalization

    Key financials

    Single quarter

    04 metrics
    1. 01Revenue1,000 Mn+12%YoY
    2. 02EBITDA Margin17%
    3. 03PAT₹91 Cr+4.0%YoY
    4. 04Net Debt-to-EBITDA2.7 ratio

    Segment breakdown

    CDMO
    15% Revenue Growth54% Innovation Revenue Share
    Complex Hospital Generics
    300 Mn Revenue44% Sevoflurane US Market Share
    India Consumer Healthcare
    ₹1,000 Cr Revenue20% Power Brand Growth
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Consolidated Revenue Growth
    mid-single-digit
    		High
    Revenue
    Consolidated Revenue Growth
    mid- to high-teen
    		Medium
    Margin
    EBITDA Margin
    19% to 20%
    		Medium
    Other
    FY30 Aspiration Revenue
    $2 billion
    		Medium
    Capex
    Annual Capex
    $100 million to $125 million
    		High
    Debt
    Net Debt-to-EBITDA Ratio
    1:1
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Customer Concentration & Inventory Normalization

    A single large CDMO customer's inventory pause will lead to muted growth and margin compression in FY26. — Management acknowledged

    high

    Biotech Funding Environment

    Uneven recovery in biotech funding is prolonging decision-making for early-stage discovery projects. — Both acknowledged

    medium

    Geopolitical & Regulatory Uncertainty

    Uncertainty around the BIOSECURE Act and trade tariffs is causing customers to delay reshoring decisions. — Management acknowledged

    medium

    Areas of Evasion(2)

    • Specific quantified targets for the $180M commercial sales carve-out in FY26.
    • Specific regulatory timelines for Phase III projects moving to commercial.

    Q&A highlights

    3

    “We have a single customer... as part of their launch program, they built a significant amount of stock to plan for success... we don't anticipate much ordering from that customer in the upcoming year.”

    Explains the primary reason for the 'muted' FY26 guidance, attributing it to a specific inventory cycle rather than a structural business decline.

    asked by Amey Chalke, JM Financial

    2 min read5 chapters

    Detailed Narrative

    01

    FY25: A Year of Milestone Achievements

    Piramal Pharma achieved a significant milestone in FY25, surpassing USD 1 billion in annual revenue with a 12% YoY growth rate. This performance was bolstered by the CDMO segment's 15% growth and the India Consumer Healthcare business crossing the ₹1,000 crore revenue mark. Profitability saw a massive jump, with PAT increasing 5x to ₹91 crores, driven by improved operating leverage and a better revenue mix.

    02

    CDMO: Innovation Pivot Drives Growth

    The CDMO business is increasingly shifting toward innovation-related work, which now accounts for 54% of segment revenue, up from 45% in FY23. On-patent commercial manufacturing revenue grew from $52 million in FY23 to $179 million in FY25. Management highlighted strong demand for differentiated capabilities like Antibody-Drug Conjugates (ADCs), peptides, and sterile injectables, which now represent 49% of CDMO revenue.

    03

    FY26: The Inventory Normalization Headwind

    Management proactively guided for a 'muted' FY26, expecting only mid-single-digit consolidated revenue growth. This is primarily due to a 'blockbuster' on-patent product customer pausing orders to normalize inventory after a heavy build-up during their launch phase in FY24-25. This temporary slowdown is expected to cause negative operating leverage, pulling EBITDA margins down to the mid-teen level for the year before a projected recovery in FY27.

    04

    Strategic US Expansion and Onshoring Readiness

    The company announced a $90 million expansion across its Lexington and Riverview sites in the US to capitalize on the growing demand for ADCs and sterile injectables. Management believes they are 'best positioned' to benefit from the BIOSECURE Act and potential trade tariffs, as they already possess a diversified network of facilities in the US and UK. These expansions are expected to come online and contribute meaningfully by FY27.

    05

    Complex Hospital Generics: Expanding Beyond the US

    The CHG business crossed $300 million in revenue, maintaining dominant market shares in the US for Sevoflurane (44%) and Baclofen (75%). To drive future growth, Piramal is targeting the $400 million Rest of World (RoW) market. Commercial production of Sevoflurane recently commenced at the Digwal facility in India, which will serve as a key driver for market share expansion in non-US geographies over the next 3-5 years.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.